FP
Flagship Pioneering Portfolio holdings
AUM
$268M
This Quarter Return
+46.2%
1 Year Return
-54.4%
3 Year Return
-51.2%
5 Year Return
+66.7%
10 Year Return
–
AUM
$7.83B
AUM Growth
+$7.83B
(+25%)
Cap. Flow
-$7.04M
Cap. Flow
% of AUM
-0.09%
Top 10 Holdings %
Top 10 Hldgs %
99.18%
Holding
12
New
–
Increased
–
Reduced
1
Closed
–
Top Buys
No buys this quarter
Top Sells
| 1 |
Seres Therapeutics
MCRB
|
$7.04M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Moderna
MRNA
$9.37B
| $4.84B | 61.77% |
20,581,016
| – | – |
|
|
RUBY
2
DELISTED
Rubius Therapeutics, Inc
RUBY
| $940M | 12.01% |
38,506,526
| – | – |
|
3
Sana Biotechnology
SANA
$777M
| $673M | 8.6% |
34,239,018
| – | – |
|
|
4
Seres Therapeutics
MCRB
$166M
| $343M | 4.38% |
14,378,802
-295,171
| -2% | -$7.04M |
|
|
EVLO
5
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
| $316M | 4.04% |
23,030,069
| – | – |
|
6
Denali Therapeutics
DNLI
$2.23B
| $214M | 2.74% |
2,730,263
| – | – |
|
|
KLDO
7
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
| $146M | 1.86% |
19,575,710
| – | – |
|
8
Foghorn Therapeutics
FHTX
$286M
| $135M | 1.73% |
12,674,120
| – | – |
|
|
SGTX
9
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
| $111M | 1.42% |
10,370,369
| – | – |
|
|
AXLA
10
DELISTED
Axcella Health Inc. Common Stock
AXLA
| $50.3M | 0.64% |
12,548,414
| – | – |
|
|
CDAK
11
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
| $48.3M | 0.62% |
2,607,303
| – | – |
|
|
SYRS
12
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $16M | 0.2% |
2,938,494
| – | – |
|